Clinical and Experimental Hepatology最新文献

{"title":"Extra-hepatic portal vein thrombosis in children: Single center experience.","authors":"Tawhida Yassin Abdel-Ghaffar,&nbsp;Haidy Mohammed Zakaria,&nbsp;Suzan El Naghi,&nbsp;Solaf M Elsayed,&nbsp;Alaa Haseeb,&nbsp;Gihan Ahmed Sobhy","doi":"10.5114/ceh.2023.125840","DOIUrl":"https://doi.org/10.5114/ceh.2023.125840","url":null,"abstract":"<p><strong>Aim of the study: </strong>We aimed to discuss our experience in management of children with extra-hepatic portal vein thrombosis (EHPVT).</p><p><strong>Material and methods: </strong>This retrospective cohort study included 62 children with EHPVT. All patients' records were reviewed. The patients' socio-demographic data, post-natal history, disease presentation and clinical examination were collected. Data from laboratory investigations - complete blood count, liver function tests, renal function tests, abdominal ultrasound/Doppler studies, upper endoscopic findings and treatment regimens - were collected whenever available.</p><p><strong>Results: </strong>Of the 62 patients, 62.9% were male and 37.1% were female. The mean age at disease presentation was 3.5 ±2.7 years. The main initial clinical presentation of the disease was hematemesis and/or melena (30 cases; 48.4%). History of umbilical catheterization (UVC) was present in 60% of cases. The thrombophilia profile was assessed in 17 patients, of whom 12 (70.6%) were found to have a coagulation disorder. Splenomegaly was present in 91.7% of the patients. Hematological abnormalities in the form of cytopenias were present in most cases. Ultrasound revealed the presence of collaterals in 76.2%. Upper endoscopy showed the presence of varices in 45 cases, all of which needed endoscopic intervention, while in 11 cases the varices were either low grade or absent and thus were subjected only to medical treatment with propranolol and 6 cases were lost to follow-up. Splenectomy was done in only one case and 2 cases underwent the Rex operation.</p><p><strong>Conclusions: </strong>Variceal bleeding is the most common clinical presentation of EHPVT in children. UVC is still the main etiological factor of EHPVT in our cohort especially with presence of thrombophilic disorder.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"9 1","pages":"37-45"},"PeriodicalIF":1.5,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/47/73/CEH-9-50341.PMC10090991.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9686904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of microRNAs in hepatocellular carcinoma: Therapeutic targeting of tumor suppressor and oncogenic genes","authors":"Nasim Rahimi Farsi, Bahman Naghipour, Parviz Shahabi, Reza Safaralizadeh, Khalil Hajiasgharzadeh, Narges Dastmalchi, Mohammad Reza Alipour","doi":"10.5114/ceh.2023.131669","DOIUrl":"https://doi.org/10.5114/ceh.2023.131669","url":null,"abstract":"AMA Farsi N, Naghipour B, Shahabi P, et al. The role of microRNAs in hepatocellular carcinoma: Therapeutic targeting of tumor suppressor and oncogenic genes. Clinical and Experimental Hepatology - Manuscripts Accepted. 2023. doi:10.5114/ceh.2023.131669. APA Farsi, N., Naghipour, B., Shahabi, P., Safaralizadeh, R., Hajiasgharzadeh, K., & Dastmalchi, N. et al. (2023). The role of microRNAs in hepatocellular carcinoma: Therapeutic targeting of tumor suppressor and oncogenic genes. Clinical and Experimental Hepatology - Manuscripts Accepted. https://doi.org/10.5114/ceh.2023.131669 Chicago Farsi, Nasim Rahimi, Bahman Naghipour, Parviz Shahabi, Reza Safaralizadeh, Khalil Hajiasgharzadeh, Narges Dastmalchi, and Mohammad Reza Alipour. 2023. \"The role of microRNAs in hepatocellular carcinoma: Therapeutic targeting of tumor suppressor and oncogenic genes\". Clinical and Experimental Hepatology - Manuscripts Accepted. doi:10.5114/ceh.2023.131669. Harvard Farsi, N., Naghipour, B., Shahabi, P., Safaralizadeh, R., Hajiasgharzadeh, K., Dastmalchi, N., and Alipour, M. (2023). The role of microRNAs in hepatocellular carcinoma: Therapeutic targeting of tumor suppressor and oncogenic genes. Clinical and Experimental Hepatology - Manuscripts Accepted. https://doi.org/10.5114/ceh.2023.131669 MLA Farsi, Nasim Rahimi et al. \"The role of microRNAs in hepatocellular carcinoma: Therapeutic targeting of tumor suppressor and oncogenic genes.\" Clinical and Experimental Hepatology - Manuscripts Accepted, 2023. doi:10.5114/ceh.2023.131669. Vancouver Farsi N, Naghipour B, Shahabi P, Safaralizadeh R, Hajiasgharzadeh K, Dastmalchi N et al. The role of microRNAs in hepatocellular carcinoma: Therapeutic targeting of tumor suppressor and oncogenic genes. Clinical and Experimental Hepatology - Manuscripts Accepted. 2023. doi:10.5114/ceh.2023.131669.","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"69 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135840347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Concomitant diverticulosis among patients undergoing liver transplantation. Does it influence the length of hospitalization after the procedure?","authors":"Tomasz Menżyk, Lubomir Skladany, Svetlana Adamcova-Selcanova, Janka Vnencakova, Daniela Zilincanova, Natalia Bystrianska, Dorota Hudy, Magdalena Skonieczna, Wojciech Marlicz, Michał Kukla","doi":"10.5114/ceh.2023.132255","DOIUrl":"https://doi.org/10.5114/ceh.2023.132255","url":null,"abstract":"AMA Menżyk T, Skladany L, Adamcova-Selcanova S, et al. Concomitant diverticulosis among patients undergoing liver transplantation. Does it influence the length of hospitalization after the procedure?. Clinical and Experimental Hepatology - Manuscripts Accepted. 2023. doi:10.5114/ceh.2023.132255. APA Menżyk, T., Skladany, L., Adamcova-Selcanova, S., Vnencakova, J., Zilincanova, D., & Bystrianska, N. et al. (2023). Concomitant diverticulosis among patients undergoing liver transplantation. Does it influence the length of hospitalization after the procedure?. Clinical and Experimental Hepatology - Manuscripts Accepted. https://doi.org/10.5114/ceh.2023.132255 Chicago Menżyk, Tomasz, Lubomir Skladany, Svetlana Adamcova-Selcanova, Janka Vnencakova, Daniela Zilincanova, Natalia Bystrianska, and Dorota Hudy et al. 2023. \"Concomitant diverticulosis among patients undergoing liver transplantation. Does it influence the length of hospitalization after the procedure?\". Clinical and Experimental Hepatology - Manuscripts Accepted. doi:10.5114/ceh.2023.132255. Harvard Menżyk, T., Skladany, L., Adamcova-Selcanova, S., Vnencakova, J., Zilincanova, D., Bystrianska, N., Hudy, D., Skonieczna, M., Marlicz, W., and Kukla, M. (2023). Concomitant diverticulosis among patients undergoing liver transplantation. Does it influence the length of hospitalization after the procedure?. Clinical and Experimental Hepatology - Manuscripts Accepted. https://doi.org/10.5114/ceh.2023.132255 MLA Menżyk, Tomasz et al. \"Concomitant diverticulosis among patients undergoing liver transplantation. Does it influence the length of hospitalization after the procedure?.\" Clinical and Experimental Hepatology - Manuscripts Accepted, 2023. doi:10.5114/ceh.2023.132255. Vancouver Menżyk T, Skladany L, Adamcova-Selcanova S, Vnencakova J, Zilincanova D, Bystrianska N et al. Concomitant diverticulosis among patients undergoing liver transplantation. Does it influence the length of hospitalization after the procedure?. Clinical and Experimental Hepatology - Manuscripts Accepted. 2023. doi:10.5114/ceh.2023.132255.","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"57 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135704890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methotrexate-induced hepatotoxicity in rats and the therapeutic properties of vitamin E: a histopathologic and flowcytometric study","authors":"Ahmet U. Akman, Zuleyha Erisgin, Sibel Turedi, Yavuz Tekelioglu","doi":"10.5114/ceh.2023.132251","DOIUrl":"https://doi.org/10.5114/ceh.2023.132251","url":null,"abstract":"AMA Akman A, Erisgin Z, Turedi S, Tekelioglu Y. Methotrexate-induced hepatotoxicity in rats and the therapeutic properties of vitamin E: a histopathologic and flowcytometric study. Clinical and Experimental Hepatology - Manuscripts Accepted. 2023. doi:10.5114/ceh.2023.132251. APA Akman, A., Erisgin, Z., Turedi, S., & Tekelioglu, Y. (2023). Methotrexate-induced hepatotoxicity in rats and the therapeutic properties of vitamin E: a histopathologic and flowcytometric study. Clinical and Experimental Hepatology - Manuscripts Accepted. https://doi.org/10.5114/ceh.2023.132251 Chicago Akman, Ahmet U., Zuleyha Erisgin, Sibel Turedi, and Yavuz Tekelioglu. 2023. \"Methotrexate-induced hepatotoxicity in rats and the therapeutic properties of vitamin E: a histopathologic and flowcytometric study\". Clinical and Experimental Hepatology - Manuscripts Accepted. doi:10.5114/ceh.2023.132251. Harvard Akman, A., Erisgin, Z., Turedi, S., and Tekelioglu, Y. (2023). Methotrexate-induced hepatotoxicity in rats and the therapeutic properties of vitamin E: a histopathologic and flowcytometric study. Clinical and Experimental Hepatology - Manuscripts Accepted. https://doi.org/10.5114/ceh.2023.132251 MLA Akman, Ahmet U. et al. \"Methotrexate-induced hepatotoxicity in rats and the therapeutic properties of vitamin E: a histopathologic and flowcytometric study.\" Clinical and Experimental Hepatology - Manuscripts Accepted, 2023. doi:10.5114/ceh.2023.132251. Vancouver Akman A, Erisgin Z, Turedi S, Tekelioglu Y. Methotrexate-induced hepatotoxicity in rats and the therapeutic properties of vitamin E: a histopathologic and flowcytometric study. Clinical and Experimental Hepatology - Manuscripts Accepted. 2023. doi:10.5114/ceh.2023.132251.","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"2010 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135704916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study of the association between a <i>MICA</i> gene polymorphism and cholangiocarcinoma in Egyptian patients.","authors":"Adel A-H Abdel-Rahman,&nbsp;Moshera Abdallah Hassan Farag,&nbsp;Mary Naguib,&nbsp;Eman Abdelsameea,&nbsp;Hamed M Abdel-Bary","doi":"10.5114/ceh.2022.122293","DOIUrl":"https://doi.org/10.5114/ceh.2022.122293","url":null,"abstract":"<p><strong>Introduction: </strong>An inflammatory environment is the common pathway for the development of cholangiocarcinoma (CCA). The natural killer group 2D receptor (NKG2D), an activating receptor for NK cells, is a potent immune axis in the antitumor and antimicrobial immune response through its binding to NKG2D ligands (NKG2DLs). NKG2DLs are normally absent or poorly expressed in most cells; conversely, they are upregulated in stressed cells. We studied the rs2596542 polymorphism located upstream of the <i>MICA</i> gene, which encodes an NKG2DL, in patients with CCA as a marker for early disease detection and a possible therapeutic target.</p><p><strong>Material and methods: </strong>A case-control study was conducted on 40 patients with CCA and 45 healthy individuals (as controls). After routine examination, the rs2596542 polymorphism of the <i>MICA</i> gene was investigated using real-time PCR.</p><p><strong>Results: </strong>We found that a TT homozygous genotype was significantly predominant in patients with CCA (<i>p</i> = 0.039), with the T allele being dominantly distributed in CCA (<i>p</i> = 0.007). High levels of CA19-9 were significantly associated with the TT genotype in the patients. However, we did not detect significant differences in rs2596542C/T genotype and allele distribution between patients with CCA with cirrhosis and those without cirrhosis (<i>p</i> > 0.05).</p><p><strong>Conclusions: </strong>The MICA rs2596542 polymorphism may affect the susceptibility to CCA, but not its progression. The TT genotype could be used as a potential diagnostic marker for CCA and triggering the MICA pathway could be a promising therapeutic target.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"8 4","pages":"293-299"},"PeriodicalIF":1.5,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/74/35/CEH-8-48663.PMC9850301.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10635056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics and predictors of short-term mortality in decompensated cirrhotic patients with acute-on-chronic liver failure.","authors":"Ahmed Abudeif,&nbsp;Eman Khalifa Al Sayed,&nbsp;Ghada Moustapha Galal","doi":"10.5114/ceh.2022.122332","DOIUrl":"https://doi.org/10.5114/ceh.2022.122332","url":null,"abstract":"<p><strong>Aim of the study: </strong>We aimed to investigate the characteristics of acute-on-chronic liver failure (ACLF) and factors associated with 28-day mortality in patients with ACLF.</p><p><strong>Material and methods: </strong>This prospective study included ACLF patients based on the European Association for the Study of the Liver-Chronic Liver Failure (EASL-CLIF) Consortium criteria, admitted between March 2021 and February 2022. We examined variables associated with 28-day mortality using multivariate Cox regression analysis.</p><p><strong>Results: </strong>Of 326 patients admitted with acute decompensation (AD) of cirrhosis, 109 (33.44%) patients were diagnosed with ACLF (mean age 63.61 ±11.15 years, 65.14% males). Of these, 26.61%, 35.78%, and 37.61% of patients were in ACLF grades 1, 2, and 3 respectively. HCV (80.73%) was the main aetiology of cirrhosis. Upper gastrointestinal bleeding (25.69%) was the most common trigger. Kidney failure (73.39%) was the most common organ failure. The 28-day mortality rate was 66.97%. Cox regression analysis revealed that the existence of 2 (HR = 6.99, 95% CI: 2.68-18.25, <i>p</i> < 0.0001) or ≥ 3 (HR = 9.34, 95% CI: 3.6-24.74, <i>p</i> < 0.0001) organ failures, hepatic encephalopathy (HR = 2.96, 95% CI: 1.27-6.94, <i>p</i> = 0.01), and elevated serum bilirubin (HR = 1.03, 95% CI: 1.00-1.06, <i>p</i> = 0.04) were independent predictors for 28-day mortality, while shifting blood pH to the normal range was associated with a decrease in the HR of ACLF mortality (HR = 0.03, 95% CI: 0.002-0.44, <i>p</i> = 0.01).</p><p><strong>Conclusions: </strong>ACLF has a very high 28-day mortality, which is associated with the existence of 2 or more organ failures, hepatic encephalopathy, elevated serum bilirubin, and low blood pH.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"8 4","pages":"300-308"},"PeriodicalIF":1.5,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e7/4b/CEH-8-48689.PMC9850305.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10580223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of sofosbuvir/ledipasvir in hepatitis C virus infection in children and adolescents with malignancy: tertiary center experience.","authors":"Mohammad Fadhil Ibraheem,&nbsp;Hasanein Habeeb Ghali,&nbsp;Falah Hasan Kareem,&nbsp;Ali Duraid Alqazaz","doi":"10.5114/ceh.2022.122278","DOIUrl":"https://doi.org/10.5114/ceh.2022.122278","url":null,"abstract":"<p><strong>Aim of the study: </strong>To determine the outcome of concomitant treatment of chronic hepatitis C virus (HCV) in children with malignant disease.</p><p><strong>Material and methods: </strong>This was a prospective cohort study conducted at a gastroenterology and hepatology outpatient clinic in a children's welfare teaching hospital/medical city complex, Baghdad, from January 2018 to October 2020 and included 30 child and adolescent patients who contracted HCV while receiving treatment for malignant diseases. Data collected included those of medical history, physical examination, and periodic clinical and laboratory evaluation during their follow-up. Their age (at the time of diagnosis of HCV) ranged between 3.2 and 15.3 years, the mean age was 8.3 years, with male predominance of 60%.</p><p><strong>Results: </strong>Sustained virologic response at post-treatment week 12 (SVR12) was obtained in all patients, 30/30 (100%), with gradual dramatic improvements of the liver enzymes, TSB, serum creatinine, and serum albumin. No serious side effects were registered, nor was there any treatment discontinuation or death. Tiredness was the most common side effect 10/30 (33.3%) in all patients.</p><p><strong>Conclusions: </strong>A combination of the ledipasvir plus sofosbuvir regimen for 12 weeks is effective and well tolerated, and can be used safely in treating children older than 3 years and adolescent patients with chronic hepatitis C.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"8 4","pages":"315-320"},"PeriodicalIF":1.5,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a5/19/CEH-8-48660.PMC9850300.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10580217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictors of early bleeding after endoscopic variceal ligation for esophageal varices: a systematic review and meta-analysis.","authors":"Suprabhat Giri,&nbsp;Sridhar Sundaram,&nbsp;Vaneet Jearth,&nbsp;Sukanya Bhrugumalla","doi":"10.5114/ceh.2022.123096","DOIUrl":"https://doi.org/10.5114/ceh.2022.123096","url":null,"abstract":"<p><strong>Aim of the study: </strong>Endoscopic variceal ligation (EVL) is important for emergency as well as prophylactic management of esophageal varices. Early bleeding after EVL is associated with significant morbidity and mortality. Assessing the likelihood of early post-EVL bleeding and its determinants can help deciding therapeutic strategies for high-risk patients. The aim of the present meta-analysis was to identify predictors of early bleeding after EVL.</p><p><strong>Material and methods: </strong>A comprehensive search of the literature was conducted from 2000 to November 2021 for studies evaluating the incidence, predictors and outcome of post-EVL bleeding. Pooled odds ratios (OR), mean difference (MD) and their 95% confidence intervals (CI) were calculated for prognostic variables.</p><p><strong>Results: </strong>A total of 16 studies with data on 13,378 patients were included in the meta-analysis. Among 34 parameters, 14 parameters were assessed for association with early bleeding after EVL. Lower hemoglobin at admission (MD = 1.11, 95% CI: -1.91 to -0.31), higher MELD score (MD = 2.00, 95% CI: 0.51-3.50), associated gastric varices (OR = 5.99, 95% CI: 1.06-33.90), higher number of bands (MD = 0.49, 95% CI: 0.02-0.97), and peptic esophagitis (OR = 11.38, 95% CI: 1.21-106.81) were significantly associated with increased risk of bleeding. However, there was significant heterogeneity among the studies with respect to all the analyzed parameters.</p><p><strong>Conclusions: </strong>Major predictors for early post-EVL bleeding in cirrhosis are admission hemoglobin level and MELD score, associated gastric varices, number of bands deployed during EVL, and peptic esophagitis on follow-up endoscopy. These risk factors may be useful for risk stratification after EVL in cirrhotics.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"8 4","pages":"267-277"},"PeriodicalIF":1.5,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2b/63/CEH-8-49349.PMC9850299.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10580219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autoantibodies: are they a clue for liver diseases?","authors":"Salma Abdel Megeed Nagi,&nbsp;Bassam Abdel Hakam Ayoub,&nbsp;Mohammed Abdel-Hafez Ali,&nbsp;Sally Waheed Elkhadry,&nbsp;Heba Mohamed Abdallah,&nbsp;Marwa Sabry Rizk","doi":"10.5114/ceh.2022.122275","DOIUrl":"https://doi.org/10.5114/ceh.2022.122275","url":null,"abstract":"<p><strong>Introduction: </strong>Autoantibody testing has contributed to both biological and clinical insights in managing patients with liver disease. These autoantibodies often have clinical value for the diagnosis, disease activity and/or prognosis.</p><p><strong>Aim of the study: </strong>We aimed to investigate the potential application of auto-antibodies in different etiologies of non-autoimmune liver diseases.</p><p><strong>Material and methods: </strong>This study was conducted on 53 infants and children with chronic liver diseases. The patients were subjected to clinical history and examination, laboratory investigations and abdominal ultrasound. Serum of all infants and children was tested for measurement of antiprothrombin antibody and anti-b2-glycoprotein I (ab2GPI) and anticardiolipin (ACL) auto-antibodies using a fully-automated enzyme linked immunosorbent assay (ELISA) system.</p><p><strong>Results: </strong>The mean age of the infants with cholestatic liver diseases was significantly lower than those with metabolic liver diseases, hepatitis C virus (HCV) and vascular liver diseases (<i>p</i> < 0.05). The gender distribution was proportionate in all groups (<i>p</i> = 0.703). Autoantibodies showed significant variations among different etiologies of chronic liver diseases. he incidence of ab2GPI and ACL was significantly increased in both HCV (94.7% and 78.9%, respectively) and vascular liver diseases patients (90.9% and 72.7%, respectively) (<i>p</i> < 0.05). Antiprothrombin antibodies were found in 81.8% of vascular liver disease patients. Interestingly, all types of autoantibodies were deficient in cholestatic and metabolic liver diseases.</p><p><strong>Conclusions: </strong>Testing for liver-related autoantibodies should be included in the workup of patients with chronic liver diseases. Further studies are needed to explain the cause-effect association of ACL, ab2GPI and antiprothrombin with chronic HCV and vascular liver diseases.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"8 4","pages":"309-314"},"PeriodicalIF":1.5,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f8/8b/CEH-8-48659.PMC9850298.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10635054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of functional magnetic resonance imaging of the brain in the evaluation of hepatic encephalopathy in cirrhotic patients.","authors":"Muhammad Ahmed Magdy Abdelhamid,&nbsp;Eman Abdelsameea,&nbsp;Enas Mohammed Korayem,&nbsp;Mohammed Shawky Alwarraky,&nbsp;Hazem Metwaly Omar","doi":"10.5114/ceh.2022.122296","DOIUrl":"https://doi.org/10.5114/ceh.2022.122296","url":null,"abstract":"<p><strong>Introduction: </strong>Hepatic encephalopathy (HE) is a complication of liver failure, with neurological manifestations ranging from minimal HE (MHE) to deep coma (overt HE).</p><p><strong>Aim of the study: </strong>To demonstrate the role of functional magnetic resonance imaging (magnetic resonance spectroscopy [MRS] and apparent diffusion coefficient [ADC] value) in the assessment and grading of HE in cirrhotic patients.</p><p><strong>Material and methods: </strong>A prospective cohort study was conducted on three groups: group I - 20 healthy controls, group II - 25 cirrhotic patients with MHE, and group III - 25 cirrhotic patients with overt HE. Each group was subjected to MRS, diffusion-weighted imaging, and neuropsychological examinations. At ¹H-MRS, the glutamate/glutamine complex (Glx), myo-inositol (mI), choline (Cho), N-acetyl aspartate (NAA), and creatine (Cr) were determined in the basal ganglia or thalamus. The metabolic ratios and ADC values of Glx/Cr, MI/Cr, Cho/Cr, and NAA/Cr were determined.</p><p><strong>Results: </strong>The brain metabolite Glx increased with a significant correlation to HE grade (<i>p</i> = 0.001). Other brain metabolites, such as Cho and mI, decreased significantly (<i>p</i> = 0.001). Two brain metabolites (NAA and Cr) remained unchanged across all HE grades and the control group (<i>p</i> = 0.47 and 0.38, respectively). There was an increase in the Glx/Cr ratio and a decrease in the mI/Cr and Cho/Cr ratios. In addition, ADC values were significantly higher in cirrhotic patients with HE than in the control group.</p><p><strong>Conclusions: </strong>ADC values and ¹H-MRS are imaging modalities that have the potential to detect MHE and grade HE in cirrhotic patients.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"8 4","pages":"321-329"},"PeriodicalIF":1.5,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6d/14/CEH-8-48664.PMC9850304.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10635057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}